<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948776</url>
  </required_header>
  <id_info>
    <org_study_id>13206</org_study_id>
    <nct_id>NCT03948776</nct_id>
  </id_info>
  <brief_title>Body Composition Ultrasound for Patients With Heart Failure</brief_title>
  <official_title>Validation of Body Composition Ultrasound for Identification of Sarcopenia and Cachexia in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether skeletal muscle ultrasound is a useful technique for
      measuring low muscle mass in patients with heart failure (HF). Muscle wasting and abnormal
      muscle quality has been identified in patients with advanced HF and may contribute to
      patients' physical limitations. However assessments of body composition for patients with HF
      currently rely on the research tool of dual X-ray absorptiometry (DXA) for measurements of
      skeletal muscle mass, which is limited by cost, use of radiation, and the need for patients
      to be transported to the DXA scanner for imaging. Therefore this observational study is
      designed to validate a new approach that allows a safe and portable assessment of body
      composition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will be recruiting both healthy subjects without HF, as well as subjects
      with either HF, a left ventricular assist device (LVAD) or cardiac transplantation. This is
      an observational study to validate the use of the BodyMetrix BX 2000 Pro ultrasound machine
      for the assessment of body composition, particularly muscle wasting. The ultrasound device
      received 501(k) designation from the FDA in 2009 for measurement of localized fat and muscle
      thickness. Participation will last for only one day, with approximately 2 hours of study
      activity in total:

        1. For woman with child-bearing potential, potential participants will be required to
           undergo a urine pregnancy test prior to DXA imaging.

        2. The investigators will record participant age, sex, height, weight and heart failure
           status.

        3. Muscle ultrasound: investigators will make measurements at 7 positions on the arm, chest
           wall, and leg (participant's dominant side). Clear ultrasound gel will be applied to the
           skin, a BodyMetrix ultrasound probe placed against the skin, and the muscle thickness
           measurement made five times at each position. The gel is then wiped away.

        4. Whole body dual X-ray absorptiometry (DXA) scan: the DXA scan involves lying on a flat
           and open scanner for approximately 5 minutes while an X-ray arm passes over the body to
           form a picture for whole body composition.

        5. Handgrip strength: this involves the participant squeezing a handheld machine on three
           occasions in the dominant hand to measure grip strength.

        6. 5 sit-to-stand test: investigators will time how long it takes for the participant to
           stand up from a seated position five times to assess lower body strength.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19
  </why_stopped>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary DXA endpoint: fat free mass (FFM) measured by DXA</measure>
    <time_frame>On study day 1</time_frame>
    <description>This is the fat free mass calculated by whole-body DXA, which is the gold standard for measuring skeletal muscle mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary ultrasound endpoint: FFM measured by BodyMetrix ultrasound</measure>
    <time_frame>On study day 1</time_frame>
    <description>This is the muscle mass estimation from the BodyMetrix ultrasound device which the investigators are seeking to validate as a method of body composition assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>On study day 1</time_frame>
    <description>Average of 3 handgrip strength measurements in the dominant upper extremity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sit-to-stand test</measure>
    <time_frame>On study day 1</time_frame>
    <description>Time (in seconds) for the participant complete 5 sit-to-stands, starting in a seated position on a chair</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Adults without HF or prior heart transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants in our existing LVAD body composition study</arm_group_label>
    <description>Currently-enrolled LVAD body composition participants, who chose to participate in this study on the same day as a DXA scan already scheduled for study #12026</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with heart failure, an LVAD or heart transplantation</arm_group_label>
    <description>Any patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inpatients with heart failure, LVAD, heart transplantation</arm_group_label>
    <description>Patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation, currently admitted as inpatients at Tufts Medical Center. The 6/20/2019 protocol update includes these patients who will participate without a DXA scan (which can only be performed as an outpatient).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BodyMetrix body composition ultrasound</intervention_name>
    <description>Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Participants in our existing LVAD body composition study</arm_group_label>
    <arm_group_label>Patients with heart failure, an LVAD or heart transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BodyMetrix body composition ultrasound only</intervention_name>
    <description>Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.</description>
    <arm_group_label>Inpatients with heart failure, LVAD, heart transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Three study populations will be recruited for this observational validation study:

        Cohort 1: Healthy volunteers Cohort 2: Participants in our existing left ventricular assist
        device (LVAD) body composition study (#12026) who consent to undergo skeletal muscle
        ultrasound the same day as an LVAD body composition study visit that already includes the
        DXA and handgrip strength procedures Cohort 3: Patients with heart failure, an LVAD or
        heart transplantation Cohort 4: Inpatients with heart failure, an LVAD or heart
        transplantation, currently admitted to Tufts Medical Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cohort 1: Healthy volunteers:

               -  18+ years

               -  No history of heart failure

               -  Not pregnant

               -  Willing to take a urinary pregnancy test if there is a possibility of pregnancy

               -  Able to freely provide informed consent

          2. Cohort 2: Participants in our existing left ventricular assist device (LVAD) body
             composition study (#12026) who consent to undergo skeletal muscle ultrasound the same
             day as an LVAD body composition study visit that already includes the DXA and handgrip
             strength procedures:

             â€¢ Meet the eligibility criteria outlined in study #12026

          3. Cohort 3: Patients with heart failure, an LVAD or heart transplantation

               -  18+ years

               -  Not pregnant

               -  Willing to take a urinary pregnancy test if there is a possibility of pregnancy

        Exclusion Criteria:

          1. Patients requiring temporary mechanical circulatory support

          2. Pregnant women, or women who report there is a possibility they could be pregnant and
             decline to complete a pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda R Vest, MBBS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>SARCUS working group on behalf of the Sarcopenia Special Interest Group of the European Geriatric Medicine Society. Perkisas S, Baudry S et al. Application of ultrasound for muscle assessment in sarcopenia: towards standardized measurements. Eur J Med 2018. In press. doi: 10.1007/s41999-018-0104-9.</citation>
  </reference>
  <reference>
    <citation>Abe T, Fujita E, Thiebaud RS, Loenneke JP, Akamine T. Ultrasound-Derived Forearm Muscle Thickness Is a Powerful Predictor for Estimating DXA-Derived Appendicular Lean Mass in Japanese Older Adults. Ultrasound Med Biol. 2016 Sep;42(9):2341-4. doi: 10.1016/j.ultrasmedbio.2016.05.008. Epub 2016 Jun 17.</citation>
    <PMID>27321173</PMID>
  </reference>
  <reference>
    <citation>Abe T, Loenneke JP, Young KC, Thiebaud RS, Nahar VK, Hollaway KM, Stover CD, Ford MA, Bass MA, Loftin M. Validity of ultrasound prediction equations for total and regional muscularity in middle-aged and older men and women. Ultrasound Med Biol. 2015 Feb;41(2):557-64. doi: 10.1016/j.ultrasmedbio.2014.09.007. Epub 2014 Nov 25.</citation>
    <PMID>25444689</PMID>
  </reference>
  <reference>
    <citation>Takai Y, Ohta M, Akagi R, Kato E, Wakahara T, Kawakami Y, Fukunaga T, Kanehisa H. Applicability of ultrasound muscle thickness measurements for predicting fat-free mass in elderly population. J Nutr Health Aging. 2014;18(6):579-85. doi: 10.1007/s12603-013-0419-7.</citation>
    <PMID>24950147</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03948776/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

